Thus far, our results indicated that IL-33 promotes M2 macrophage polarization and an immunosuppressive TME, reducing cisplatin efficacy in lung cancer via IL-33/ST2L/NF-κB signaling and Rab37/ST2L trafficking. The gene discussed is IL33; the disease is lung carcinoma.